Bartlett & Co Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Bartlett & Co Wealth Management's CRSP Position: Q3 2026 in Review
Bartlett & Co Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 11,100 shares worth $614K. The position accounts for 0.01% of the portfolio, ranked #326.
Bartlett & Co Wealth Management first reported a position in CRSP in Q4 2021 and has held it in 20 quarters since. The position peaked at $1.03M in Q4 2021. 503 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Bartlett & Co Wealth Management held 11,100 shares of CRISPR Therapeutics worth $614K as of Q3 2026.
- Bartlett & Co Wealth Management left its CRISPR Therapeutics share count unchanged in Q3 2026.
- CRISPR Therapeutics made up 0.01% of Bartlett & Co Wealth Management's portfolio in Q3 2026, its #326 holding.
- Bartlett & Co Wealth Management first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 20 quarters since.
- Bartlett & Co Wealth Management's CRISPR Therapeutics position peaked at $1.03M in Q4 2021.
- 503 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Bartlett & Co Wealth Management's 13F filing for Q3 2026, filed 12 Nov 2026.